Tredje AP fonden Sells 3,996 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Tredje AP fonden lowered its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 50.0% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 3,996 shares of the medical research company’s stock after selling 3,996 shares during the quarter. Tredje AP fonden’s holdings in Charles River Laboratories International were worth $738,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently modified their holdings of CRL. Truvestments Capital LLC lifted its holdings in Charles River Laboratories International by 6.4% during the fourth quarter. Truvestments Capital LLC now owns 2,562 shares of the medical research company’s stock worth $473,000 after acquiring an additional 155 shares during the period. EverSource Wealth Advisors LLC increased its position in shares of Charles River Laboratories International by 10.2% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,673 shares of the medical research company’s stock valued at $309,000 after purchasing an additional 155 shares during the last quarter. Cooke & Bieler LP raised its stake in shares of Charles River Laboratories International by 42.1% during the 4th quarter. Cooke & Bieler LP now owns 426,767 shares of the medical research company’s stock worth $78,781,000 after purchasing an additional 126,372 shares during the period. Tortoise Investment Management LLC boosted its holdings in shares of Charles River Laboratories International by 77.7% in the 4th quarter. Tortoise Investment Management LLC now owns 263 shares of the medical research company’s stock worth $49,000 after buying an additional 115 shares during the last quarter. Finally, Daiwa Securities Group Inc. grew its position in Charles River Laboratories International by 7.3% during the fourth quarter. Daiwa Securities Group Inc. now owns 6,820 shares of the medical research company’s stock valued at $1,259,000 after buying an additional 465 shares during the period. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Insider Buying and Selling at Charles River Laboratories International

In related news, COO Birgit Girshick acquired 1,514 shares of the stock in a transaction dated Thursday, February 20th. The shares were purchased at an average price of $164.63 per share, for a total transaction of $249,249.82. Following the transaction, the chief operating officer now owns 55,058 shares in the company, valued at $9,064,198.54. This represents a 2.83 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Joseph W. Laplume sold 4,400 shares of the company’s stock in a transaction on Thursday, February 20th. The stock was sold at an average price of $162.50, for a total transaction of $715,000.00. Following the completion of the transaction, the executive vice president now owns 20,013 shares of the company’s stock, valued at $3,252,112.50. This trade represents a 18.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 1.30% of the company’s stock.

Charles River Laboratories International Stock Performance

Charles River Laboratories International stock opened at $171.27 on Friday. Charles River Laboratories International, Inc. has a 1-year low of $150.79 and a 1-year high of $274.77. The company has a current ratio of 1.41, a quick ratio of 1.14 and a debt-to-equity ratio of 0.65. The firm has a market capitalization of $8.76 billion, a PE ratio of 1,141.78, a price-to-earnings-growth ratio of 4.54 and a beta of 1.45. The firm’s 50 day simple moving average is $167.74 and its 200 day simple moving average is $184.59.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings results on Wednesday, February 19th. The medical research company reported $2.66 earnings per share for the quarter, topping the consensus estimate of $2.50 by $0.16. The firm had revenue of $1 billion for the quarter, compared to analysts’ expectations of $983.63 million. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The business’s quarterly revenue was down 1.1% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.46 earnings per share. As a group, analysts expect that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research firms have weighed in on CRL. Citigroup upgraded shares of Charles River Laboratories International from a “sell” rating to a “neutral” rating and boosted their target price for the company from $155.00 to $175.00 in a research note on Tuesday, March 4th. JPMorgan Chase & Co. reduced their price objective on Charles River Laboratories International from $175.00 to $165.00 and set a “neutral” rating for the company in a report on Thursday, February 20th. Morgan Stanley lowered their target price on Charles River Laboratories International from $220.00 to $184.00 and set an “equal weight” rating on the stock in a research note on Wednesday, February 5th. Robert W. Baird cut their price target on Charles River Laboratories International from $177.00 to $173.00 and set a “neutral” rating for the company in a research note on Thursday, February 20th. Finally, Redburn Atlantic raised Charles River Laboratories International from a “sell” rating to a “neutral” rating and set a $188.00 price objective for the company in a report on Monday, March 3rd. One analyst has rated the stock with a sell rating, fifteen have issued a hold rating and one has given a buy rating to the company. According to data from MarketBeat.com, Charles River Laboratories International currently has a consensus rating of “Hold” and a consensus price target of $198.36.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).